AbbVie Deutschland GmbH & Co. KG

The organisation conducts extensive investigations in haematological malignancies and solid tumours. Research focuses on chronic lymphocytic leukaemia, follicular lymphoma, mantle cell lymphoma, and acute myeloid leukaemia, examining targeted therapies including BCL-2 inhibitors and BTK inhibitors. Studies explore combination regimens with chemotherapy, immunotherapy, and novel targeted agents.

• Haematological Malignancies
• Solid Tumour Investigations
• Combination Oncology Therapies
• Minimal Residual Disease Assessment

The research programme evaluates progression-free survival, overall survival, and complete response rates across various cancer types. Investigations include treatment strategies for relapsed or refractory disease, first-line therapies, and maintenance approaches following initial treatment success.

The sponsor pursues research addressing central nervous system disorders with significant unmet medical needs. Studies investigate Parkinson's disease, examining motor and non-motor symptoms, dyskinesia, and disease progression. Research extends to major depressive disorder, exploring novel therapeutic mechanisms and treatment-resistant populations.

• Movement Disorders
• Mood and Affective Disorders
• Neurodegenerative Conditions
• Cognitive Function Assessment

Investigations employ validated rating scales including UPDRS for motor function assessment and MADRS for depression severity. Research encompasses both symptomatic management and potential disease-modifying approaches, with particular attention to quality of life improvements and functional outcomes.

The research portfolio includes substantial investment in inflammatory skin diseases, particularly atopic dermatitis, psoriasis, and hidradenitis suppurativa. Studies evaluate systemic therapies, topical treatments, and combination approaches targeting various inflammatory pathways. Research addresses both adult and paediatric populations across different disease severities.

• Chronic Inflammatory Skin Diseases
• Pruritus and Symptom Management
• Skin Barrier Function
• Disease Severity Assessment Tools

Investigations utilise standardised outcome measures including EASI scores, PASI scores, and IGA assessments to evaluate treatment efficacy. Research explores long-term safety profiles, quality of life impacts, and therapeutic responses in patients with prior treatment failures or contraindications to existing therapies.

The sponsor conducts research in chronic liver diseases, with emphasis on chronic hepatitis C and its complications. Studies examine antiviral therapies, treatment durations, and outcomes in diverse patient populations including those with cirrhosis and hepatocellular carcinoma. Research extends to IgA nephropathy, investigating disease progression and therapeutic interventions.

• Viral Hepatitis Management
• Chronic Kidney Diseases
• Liver Fibrosis and Cirrhosis
• Sustained Virological Response

Investigations assess SVR rates, proteinuria reduction, and long-term organ function preservation. Research incorporates real-world evidence studies and registry-based investigations to complement controlled clinical trials, examining treatment outcomes across various demographic and clinical subgroups.